股票简称：海正药业 股票代码：600267 公告编号：临 2024-69 号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 企业名称：浙江海正动物保健品有限公司 生产地址：浙江省杭州市富阳区东洲街道高尔夫路 208 号 二、产品基本情况 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的赛拉菌素滴剂兽药产品批准文号批件。现就相关情况公告如下： 一、批件基本信息 通用名称：赛拉菌素滴剂 兽药产品批准文号：兽药字 110803395、兽药字 110803396、兽药字 110803397、 兽药字 110803398、兽药字 110803399、兽药字 110803400 批准文号有效期：2024-05-07 至 2029-05-06 商品名称：赛乐滴 含量规格 ： 0.25ml:15mg ； 0.75ml:45m ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：临 | 2024-58 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110813 | 债券简称：海正定转 | | | | 浙江海正药业股份有限公司 关于"海正定转"可选择回售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： i：指可转换公司债券当年票面利率； 公司的股票自2024年3月18日至2024年4月30日连续30个交易日的收盘价格低 于本公司"海正定转"当期转股价格的80％。根据《交易报告书》的约定，"海 正定转"回售条款生效。 现依据《上市公司证券发行注册管理办法》《可转换公司债券管理办法》《上 回售价格：100.00 元人民币/张（含当期利息） 回售期：2024 年 5 月 13 日至 2024 年 5 月 17 日 回售资金发放日：2024 年 5 月 22 日 回售期内"海正定转"停止转股 本次回售不具有强制性 证券停复牌情况：适用 海证券交易所股票上市规则》和公司《交易报告书》 ...

| 证券简称：海正药业 | 证券代码：600267 | 公告编号：2024-57 号 | | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | 浙江海正药业股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 5 月 13 日（星期一）至 5 月 17 日（星期五）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券管理部邮箱 stock600267@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 二、说明会召开的时间、地点 浙江海正药业股份有限公司（以下简称"公司"）已于本公告日发布公司 2023 年年度报告、2024 年第一季度报告，为便于广大投资者更全面深入地了解公司 2023 年度及 20 ...

Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 248,531,288.09, representing an increase of 6.99% year-on-year [13]. - Operating revenue for Q1 2024 was CNY 2,726,615,253.70, down 11.00% compared to the same period last year [13]. - Basic earnings per share for Q1 2024 were CNY 0.21, reflecting a growth of 10.53% compared to the previous year [13]. - Diluted earnings per share for Q1 2024 were CNY 0.21, an increase of 23.53% year-on-year [13]. - Operating profit for Q1 2024 was CNY 272,881,031.20, compared to CNY 295,762,745.82 in Q1 2023, reflecting a decline of 7.7% [35]. - The net profit for Q1 2024 was approximately ¥246.35 million, an increase from ¥241.53 million in Q1 2023, representing a growth of about 2.5% [45]. - The total revenue for Q1 2024 was ¥270.59 million, compared to ¥295.65 million in Q1 2023, indicating a decrease of approximately 8.5% [45]. - The basic earnings per share for Q1 2024 was ¥0.21, up from ¥0.19 in Q1 2023, marking an increase of approximately 10.5% [45]. Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 17,430,133,954.21, a decrease of 1.04% compared to the end of the previous year [7]. - Total liabilities amounted to approximately ¥9.14 billion, a decrease from ¥9.26 billion in the previous period, reflecting a reduction of about 1.2% [23]. - The company's total assets were reported at approximately ¥17.43 billion, compared to ¥17.61 billion in the previous period, representing a decrease of about 1.0% [23]. - The total equity attributable to shareholders at the end of Q1 2024 was CNY 8,044,565,413.40, a decrease of 0.71% from the end of the previous year [7]. - The total equity attributable to shareholders was approximately ¥8.04 billion, down from ¥8.10 billion, indicating a decline of about 0.7% [23]. - The total current liabilities were reported at approximately ¥7.21 billion, compared to ¥6.58 billion, indicating an increase of about 9.7% [23]. - The total non-current liabilities decreased to approximately ¥1.93 billion from ¥2.68 billion, indicating a reduction of about 28.0% [23]. Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY 315,089,920.00, an increase of 3.49% year-on-year [13]. - Cash flow from operating activities in Q1 2024 was CNY 315,089,920.00, slightly up from CNY 304,464,171.32 in Q1 2023 [38]. - The company's cash outflow for operating activities in Q1 2024 was CNY 2,581,859,593.57, compared to CNY 2,992,356,769.67 in Q1 2023, indicating a reduction of 13.8% [38]. - The cash flow from investment activities showed a net outflow of ¥44.94 million in Q1 2024, compared to a net outflow of ¥130.00 million in Q1 2023, reflecting an improvement in cash management [41]. - The cash flow from financing activities resulted in a net outflow of ¥271.80 million in Q1 2024, contrasting with a net inflow of ¥47.58 million in Q1 2023, indicating a shift in financing strategy [41]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,413 [16]. - The number of shares held by the top ten shareholders included Zhejiang Haizheng Group with 320,783,590 shares, representing a significant portion of the total equity [23]. - The company plans to implement an employee stock ownership plan using shares repurchased through market transactions, which accounted for 2.18% of total shares [23]. Other Financial Metrics - The weighted average return on equity for Q1 2024 was 3.10%, an increase of 0.27 percentage points compared to the previous year [13]. - Non-recurring gains and losses included a government subsidy of CNY 13,474,807.23 and a fair value change gain of CNY 109,980,090.46 from financial assets [8]. - Long-term borrowings rose to approximately ¥1.28 billion, an increase from ¥1.12 billion, reflecting a growth of about 14.3% [23]. - The company's retained earnings increased to approximately ¥2.23 billion, up from ¥1.98 billion, showing a growth of about 12.5% [23]. - The company's cash and cash equivalents were CNY 1,568,730,864.92 as of March 31, 2024, slightly down from CNY 1,586,627,072.09 at the end of 2023 [30]. - Inventory as of March 31, 2024, was CNY 1,830,044,519.42, a decrease from CNY 1,956,874,088.91 at the end of 2023, reflecting a reduction of 6.4% [30]. - The company reported a decrease in other comprehensive income, with a net amount of -¥717,310.31 in Q1 2024 compared to -¥1,388,894.91 in Q1 2023, indicating a reduction in losses from other comprehensive income [45]. - The company raised ¥2.12 billion through financing activities in Q1 2024, compared to ¥1.40 billion in Q1 2023, showing an increase in capital acquisition efforts [41]. - The company experienced a foreign exchange impact of ¥892,114.61 on cash and cash equivalents in Q1 2024, contrasting with a negative impact of -¥827,928.55 in Q1 2023, indicating improved currency stability [41]. - The company reported a decrease in operating expenses, with non-operating expenses of ¥2.56 million in Q1 2024 compared to ¥166,327.00 in Q1 2023, reflecting better cost control measures [45].

Investment and Expansion - The total investment in the expansion of the injection production project reached CNY 46,354.12 million, with CNY 1,720.56 million invested in the current reporting period[1]. - The investment in the construction of the Metrolux production line amounted to CNY 16,329.20 million, with CNY 993.73 million invested in the current reporting period[1]. - The technical transformation project for oral solid preparations in the Ousha plant has a total investment of CNY 27,973.73 million, with CNY 4,161.09 million invested in the current reporting period[1]. - The total investment across all projects is CNY 90,657.05 million, with CNY 6,875.38 million invested in the current reporting period[1]. - The company has completed the construction of the Metrolux production line and is currently applying for product registration[1]. - The company has made significant progress in the GMP inspection of its injection production project, with some production lines already in operation[1]. - The company is preparing for trial production in the technical transformation project for oral solid preparations, with major equipment already installed and undergoing testing[1]. Research and Development - The company’s R&D investment accounted for 3.79% of its operating revenue during the reporting period[12]. - The company’s R&D investment was CNY 131,544.98 million, which is 15.17% of its operating revenue, compared to the industry average of CNY 192,840.29 million[12]. - R&D investment accounted for 4.71% of net assets during the reporting period[15]. - The capitalization ratio of R&D investment was 0.43% in the reporting period[15]. - Research and development expenses for the project HS387 amounted to CNY 21.19 million, representing a significant increase of 2861.51% compared to the previous year[55]. - The company has a total of five major R&D projects, with varying investment amounts and changes compared to the previous year[55]. - In the R&D sector, the company has received clinical approval for 2 innovative drugs and 5 generic drugs, with 3 products passing or deemed to have passed consistency evaluations, including the first domestic approval for Pravastatin Sodium Tablets[101]. - The company has applied for a total of 1,305 patents, including 1,236 invention patents, with 435 valid patents granted, showcasing its strong R&D capabilities[173]. - The company has undertaken three national key research and development projects, further enriching its product reserves and enhancing its market position[101]. Financial Performance - The net profit attributable to the parent company for 2023 was -93,171,306.60 CNY, while the parent company achieved a net profit of 379,105,746.96 CNY[28]. - The total profit available for distribution to shareholders for the year was 2,529,569,454.09 CNY after accounting for legal reserves and cash dividends[28]. - The company reported a net profit of negative value for the year 2023, leading to a proposal of no cash dividends, no bonus shares, and no capital reserve transfer to share capital[44]. - The company's total operating revenue for 2023 was approximately ¥10.37 billion, a decrease of 13.82% compared to ¥12.04 billion in 2022[77]. - The net profit attributable to shareholders was a loss of approximately ¥93.17 million, representing a decline of 119.06% from a profit of ¥488.86 million in the previous year[77]. - The net cash flow from operating activities decreased by 27.26% to approximately ¥1.50 billion, down from ¥2.07 billion in 2022[77]. - The company's total assets at the end of 2023 were approximately ¥17.61 billion, a decrease of 6.20% from ¥18.78 billion in 2022[77]. - The weighted average return on net assets was -1.15%, a decrease of 7.53 percentage points from 6.38% in the previous year[81]. - The basic earnings per share for 2023 was -¥0.08, a decrease of 119.05% from ¥0.42 in 2022[78]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of approximately ¥100.02 million in 2023 compared to a profit of ¥312.73 million in 2022, a decrease of 131.98%[77]. Sales and Marketing - The total sales expenses for the company reached CNY 1.48 billion, with marketing promotion expenses accounting for 62.41% of the total[57]. - The sales expenses for the reporting period totaled approximately ¥236.84 million, accounting for 22.83% of operating revenue[60]. - The company’s sales model has been detailed in the management discussion section of the report, highlighting its operational strategies[56]. - The company has established a nationwide sales network covering top 100 chain pharmacies, enhancing consumer access to medications[133]. - The company has integrated commercial channels and optimized marketing models, achieving growth in overall channels and innovative businesses while controlling costs and improving efficiency through various measures[93]. - The company’s marketing strategy includes a multi-channel integrated approach, covering over 16,000 medical institutions across 31 provinces in China[168]. Operational Efficiency - Employee compensation expenses amounted to 743,542,698.98 CNY, representing 31.39% of total expenses[21]. - Depreciation and amortization expenses were 62,335,869.99 CNY, accounting for 2.63% of total expenses[21]. - The company has implemented a series of management reforms to improve efficiency and reduce costs across its operations[125]. - The company has undertaken measures to optimize transportation methods and manage near-expiry products effectively, contributing to improved operational efficiency[93]. - The company has established a quality management system that meets international standards, ensuring compliance with global pharmaceutical quality requirements[161]. Market Position and Strategy - The company has been recognized as one of the top 100 pharmaceutical companies in China for 2022 and 2023, highlighting its industry influence and innovation capabilities[148]. - The company is actively expanding into emerging markets, including health and wellness sectors, to diversify its business portfolio[146]. - The company aims to enhance its product offerings in the cardiovascular and metabolic disease treatment areas, contributing to the "Healthy China 2030" initiative[106]. - The company has strengthened partnerships with major breeding groups in the animal health sector, increasing sales proportion from large clients, while also enhancing online product promotion to boost brand influence[98]. - The company has established cooperative relationships with domestic and international formulation clients, focusing on core products to enhance competitiveness in key markets like the EU and the US[97]. Challenges and Risks - The company emphasizes the importance of risk disclosure regarding forward-looking statements in its annual report[29]. - The pharmaceutical manufacturing industry in China faced challenges in 2023, with a reported revenue decline of 3.7% year-on-year[127]. - The decline in revenue from the pharmaceutical distribution business was primarily due to cautious accounting practices and changes in agency relationships[186]. - The company reported a net profit of -418 million RMB in Q4 2023, a decrease of 469 million RMB compared to Q4 2022, primarily due to the impact of centralized procurement on key products[177]. Corporate Governance - The company has engaged Tianjian Accounting Firm for auditing services, with specific auditors named[39]. - The company’s legal representative is Shen Xinghu, overseeing its operations and compliance[36]. - The company has subsidiaries including Zhejiang Hisun Pharmaceutical Co., Ltd. and others, contributing to its overall business structure[35]. - The company has established R&D centers in multiple locations, including Taizhou, Shanghai, Hangzhou, and the United States, demonstrating its full-chain drug R&D capabilities[199].

股票简称：海正药业 股票代码：600267 公告编号：临 2024-54号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 关于举办投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024年5月20日(星期一)下午15:30-17:00 会议召开地点：浙江海正药业股份有限公司（台州市椒江区外沙路46号） 会议召开方式：现场召开 浙江海正药业股份有限公司（以下简称“公司”）已于 2024 年 4 月 30 日发 布公司2023年年度报告、2024年第一季度报告，为进一步提高公司治理水平，加 强投资者关系管理，增进公司与广大投资者的沟通和交流，便于广大投资者更全 面深入地了解公司 2023 年度及 2024 年第一季度经营成果、财务状况，同时广泛 听取投资者的意见和建议，公司计划于 2024 年5月20日下午15:30-17:00举办投 资者接待日活动。本次投资者接待日活动具体情况如下： ...

| 股票简称：海正药业 | 股票代码：600267 | 公告编号：临 | 2024-42 | 号 | | --- | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | | 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司的全资子公司云南生物制药有限公司（以下简称"云生公 司"）收到中华人民共和国农业农村部核准签发的猪圆环病毒 2 型亚单位疫苗（大 肠杆菌源）兽药产品批准文号批件。现就相关情况公告如下： 一、批件基本信息 猪圆环病毒 2 型亚单位疫苗（大肠杆菌源）为三类新兽药，适用于预防由猪 圆环病毒 2 型感染引起的疾病。免疫产生期为 28 日，免疫期为 4 个月。猪圆环 病毒病（PCVD），又称为"猪圆环病毒 2 型相关疾病"，由猪圆环病毒 2 型（PCV2） 感染引起，常表现母猪繁殖障碍、断奶仔猪多系统衰竭综 ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：2024-41 | 号 | | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | 浙江海正药业股份有限公司 关于第三次股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/12/23 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购价格上限 | 13 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 11,687,200 股 | | 实际回购股数占总股本比例 | 0.97% | | 实际回购金额 | 9,899.27 万元 | | 实际回购价格区间 | 7.17 元/股~9.75 元/股 | ...

股票简称：海正药业 股票代码：600267 公告编号：临 2024-40 号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司的全资子公司云南生物制药有限公司（以下简称"云生公 司"）收到中华人民共和国农业农村部核准签发的猪圆环病毒 2 型、猪肺炎支原 体二联灭活疫苗（重组杆状病毒 DBN01 株+DJ-166 株）兽药产品批准文号批件。 现就相关情况公告如下： 一、批件基本信息 通用名称：猪圆环病毒 2 型、猪肺炎支原体二联灭活疫苗（重组杆状病毒 DBN01 株+DJ-166 株） 兽药产品批准文号：兽药生字 250121165 含量规格：20ml/瓶、100ml/瓶、250ml/瓶、500ml/瓶 企业名称：云南生物制药有限公司 生产地址：云南省昆明市高新区马金铺园区生物谷街 996 号 二、产品基本情况 猪圆环病毒 2 型、 ...

| 股票简称：海正药业 | 股票代码：600267 | 公告编号：临 | 2024-39 | 号 | | --- | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | | 浙江海正药业股份有限公司 关于不向下修正"海正定转"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 4 月 15 日，浙江海正药业股份有限公司（以下简称"公司"） 股票已出现任意连续 30 个交易日中至少有 15 个交易日的收盘价低于当前转股 价格的 90%的情形，触发"海正定转"转股价格向下修正条款。 经公司第九届董事会第二十六次会议审议通过，公司董事会决定本次不 行使"海正定转"转股价格向下修正的权利，且在未来十二个月内（2024 年 4 月 16 日至 2025 年 4 月 15 日），如再次触发可转换公司债券（以下简称"可转债"） 的转股价格向下修正条款，亦不提出向下修正方案。自 2025 年 4 月 16 日开始重 新起算，若再次触 ...